Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

R Mesía; F Rivera; A Kawecki; S Rottey; R Hitt; H Kienzer; D Cupissol; D De Raucourt; M Benasso; P Koralewski; J-P Delord; Carsten Bokemeyer; D Curran; A Gross; J B Vermorken

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Standard

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. / Mesía, R; Rivera, F; Kawecki, A; Rottey, S; Hitt, R; Kienzer, H; Cupissol, D; De Raucourt, D; Benasso, M; Koralewski, P; Delord, J-P; Bokemeyer, Carsten; Curran, D; Gross, A; Vermorken, J B.

In: ANN ONCOL, Vol. 21, No. 10, 10, 2010, p. 1967-1973.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mesía, R, Rivera, F, Kawecki, A, Rottey, S, Hitt, R, Kienzer, H, Cupissol, D, De Raucourt, D, Benasso, M, Koralewski, P, Delord, J-P, Bokemeyer, C, Curran, D, Gross, A & Vermorken, JB 2010, 'Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.', ANN ONCOL, vol. 21, no. 10, 10, pp. 1967-1973. <http://www.ncbi.nlm.nih.gov/pubmed/20335368?dopt=Citation>

APA

Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J-P., Bokemeyer, C., Curran, D., Gross, A., & Vermorken, J. B. (2010). Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ANN ONCOL, 21(10), 1967-1973. [10]. http://www.ncbi.nlm.nih.gov/pubmed/20335368?dopt=Citation

Vancouver

Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ANN ONCOL. 2010;21(10):1967-1973. 10.

Bibtex

@article{a6d3482de5fd4ddd976ab440b67bce54,

title = "Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.",

abstract = "A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL).",

author = "R Mes{\'i}a and F Rivera and A Kawecki and S Rottey and R Hitt and H Kienzer and D Cupissol and {De Raucourt}, D and M Benasso and P Koralewski and J-P Delord and Carsten Bokemeyer and D Curran and A Gross and Vermorken, {J B}",

year = "2010",

language = "Deutsch",

volume = "21",

pages = "1967--1973",

journal = "ANN ONCOL",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "10",

}

RIS

TY - JOUR

T1 - Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

AU - Mesía, R

AU - Rivera, F

AU - Kawecki, A

AU - Rottey, S

AU - Hitt, R

AU - Kienzer, H

AU - Cupissol, D

AU - De Raucourt, D

AU - Benasso, M

AU - Koralewski, P

AU - Delord, J-P

AU - Bokemeyer, Carsten

AU - Curran, D

AU - Gross, A

AU - Vermorken, J B

PY - 2010

Y1 - 2010

N2 - A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL).

AB - A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL).

M3 - SCORING: Zeitschriftenaufsatz

VL - 21

SP - 1967

EP - 1973

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 10

M1 - 10

ER -